Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by deepoil0808on Mar 18, 2024 5:53pm
437 Views
Post# 35939273

Brian Bayley sold 100,000 shares at $ 3/share

Brian Bayley sold 100,000 shares at $ 3/share Brian Baylet sold 150,000 shares of the company:

100,000 shares from options at $ 3 per share 

and,

50,000 shares from his core holdings

Owns +/- 333,000 shares.

What prompted this big selloff?   He should be sitting on about 500,000 shares instead he sold on March 12th.

Keep an eye on this to see if there are more sales done in the coming days.

Fact that observers are able to see for themselves if trials are successful or not, makes it so hard to keep anything hush....

Market plunge of late is telling us that trials may not be going as planned.

If we break $ 2.13 per share, then I would start to be concerned.

https://www.theglobeandmail.com/investing/markets/stocks/NGEN-X/insiders/

https://www.marketscreener.com/insider/BRIAN-BAYLEY-A042MG/

My personal opinion,

Good Luck, 
<< Previous
Bullboard Posts
Next >>